Where is ubiquinone in mitochondria

A significant lower level of CoQ10 is observed in cancerous tissues when compared to the normal tissues. A case-control study [ 31 , 32 ] revealed an inverse association between CoQ10 levels and incidence of breast cancer.

An in vitro study with MCF-7 breast cancer cell lines where the cells were co-incubated with CoQ10 showed results with significant decrease in intracellular peroxide formation and matrix metalloproteinase 2 activity and the effects were in a dose-dependent manner [ 33 ]. Results further showed that CoQ10 had no inhibitory effect on apoptotic, anti-growth and anti-colonization effects of doxorubicin at any doses [ 34 ].

Reports suggest that increasing the dose of CoQ10 to mg from mg for more periods revealed resolution of tumor residue without any metastases [ 36 , 37 , 38 ] and increased the survivability [ 39 ]. Daily intake of a combination of mg CoQ10, 10 mg riboflavin and 50 mg niacin reduced the circulating tumor markers [ 40 , 41 , 42 , 43 , 44 , 45 , 46 ]. Consuming a combination of CoQ10 along with lipotropic factor L-carnitine reduced the tumor-related fatigue in subjects [ 47 , 48 , 49 , 50 ]. In fast-growing broilers, the impact of ascites mortality is very high after 5 weeks of age as the farmers are not only losing the birds but also are incurring the feeding and rearing cost by the time.

Feed restriction or skip-a-day feeding is followed in broiler during finisher phase to avoid the problem of ascites, which results in poor body weight and feed efficiency. To counteract this, CoQ10 was used, and in fact, the importance of CoQ10 was felt with a reduction in ascites mortality in broilers when fed with CoQ10 [ 51 ]. Then, the term ascites heart index AHI comes into prominence, which gives more information about the susceptibility of the birds to ascites. Ascites heart index AHI , a sensitive index of pulmonary hypertension, is based on the relative ratio of the right ventricle to the total ventricle [ 52 ].

The relative heart weight of birds receiving CoQ10 at 20 mg kgG1 of diet was higher [ 54 , 55 , 56 , 57 , 58 ]. However, there was a lower heart weight with respect to percentage of body weight when broilers fed with 20 and 40 mg of CoQ10 [ 60 ]. Clinical human and animal studies suggested that dietary CoQ10 supplementation improved the cholesterol metabolism in mammals.

CoQ10 supplementation decreased plasma total cholesterol concentration in humans [ 61 ] and rats [ 62 ]. CoQ10 was reportedly able to suppress the hepatic cholesterogenesis in rats [ 63 ] and in hens [ 64 ]. The reduction in cholesterol level was due to decreased enzymatic activity of 3-hydroxymethylglutaryl coenzyme A reductase HMGR in the liver, but it had no influence on the enzymatic activity of 3-hydroxymethylglutaryl coenzyme A synthetase HMGS.

In a long-term CoQ10 feeding trial, reduced cholesterol synthesis with suppression in cholesterol catabolism was observed resulting in return of hepatic cholesterol to normal level [ 65 ]. However, long-term 0—42 days supplementation of CoQ10 at 20 and 40 mg kgG1 reduced the levels of serum total cholesterol and serum LDL cholesterol [ 58 , 66 ].

The reduction in serum LDL cholesterol due to CoQ10 supplementation was attributed to the action of reduced form of CoQ10 H2 , which induces characteristic gene expression patterns, which are translated into reduced LDL cholesterol level in human subjects.

However, there were no reports of increase in the HDL cholesterol levels [ 58 , 65 ]. CoQ10 reduced cholesterol metabolism in the plasma of patients with myocardial infarction [ 67 ] and in diabetic rats [ 62 ].

CoQ9, a major coenzyme Q in rats, decreases plasma total cholesterol concentration and suppresses hepatic cholesterogenesis [ 68 ]. Under the present intensive system of poultry production especially in tropics, stresses due to environment, metabolic, managemental, etc. Increased reactive oxygen species ROS metabolites compromise cell membrane integrity [ 53 ], which results in drip loss in muscles [ 60 ] affect keeping quality of muscles.

Different nutrients and additives like the use of synthetic amino acids, low heat increment nutrients, vitamins C, E and minerals such as selenium, zinc and magnesium or additive such as genistein and melatonin, and essential oils are tried with varied success to counteract these stresses [ 69 ].

Aside from its role in mitochondrial bioenergetics, ubiquinone also affects membrane fluidity [ 11 ] and protects membrane phospholipids against peroxidation [ 12 ].

CoQ10 in its reduced form possesses free radical scavenging and increases total antioxidant capacity [ 70 , 71 ]. Serum or liver malondialdehyde MDA is a product of lipid peroxidation and serves as a biomarker for oxidative damage in lipids.

This suggested the protective action on lipid peroxidation in liver mitochondria by CoQ Superoxide dismutase SOD activity was increased in accordance with CoQ10 supplementation in broilers and in rats [ 74 ]. This synergistic action of CoQ10 is possible as it acts as a primary regenerating antioxidant [ 75 ]. However, supplementation at 40 mg kgG1 of diet resulted in no effect on serum vitamin E and SOD levels.

This ineffectiveness of CoQ10 at 40 mg kgG1 of diet is due to the auto-oxidation of CoQ10 resulting in higher production of mitochondrial reactive oxygen species ROS , which leads to oxidative stress in the body. The development of auto-oxidation was observed in birds fed higher level of CoQ10 for prolonged duration. The content of CoQ10 in different body tissues is well studied in human subjects, but there are not enough studies in farm animals or birds.

The highest concentration of CoQ10 was found in the most active organs like heart, kidney and liver. The CoQ10 concentration depends on a balance between inputs and outputs. Inputs are the level of CoQ10, which is endogenously synthesized, plus dietary supply and the outputs are the usage by oxidative stress and cellular metabolism. An adult human body has approximately 2 g of CoQ10, where a daily replacement of 0.

Therefore, an average body CoQ10 content turnover rate was around 4 days and dietary supply becomes essential with impairment in endogenous synthesis. The body content of CoQ10 decreased rapidly after the age of 40 years in humans with reduced biosynthesis. The importance of plasma membrane coenzyme Q in aging and stress responses.

Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Thomas SR, Stocker R. Mechanisms of antioxidant action of ubiquinol for low-density lipoprotein. Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance. Independent and concerted antioxidant functions of coenzyme Q.

Coenzyme Q10 in health and disease. Eur J Clin Nutr. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. Coenzyme Q10 defects may be associated with a deficiency of Qindependent mitochondrial respiratory chain complexes. Biol Res. Age-related changes in the lipid compositions of rat and human tissues. Coenzyme Q10 Supplementation in Aging and Disease. Front Physiol. Mitochondrial aging: open questions. Ann N Y Acad Sci.

Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic Biol Med. Lapointe J, Hekimi S. J Biol Chem. Supplementation with the reduced form of coenzyme Q10 decelerates phenotypic characteristics of senescence and induces a peroxisome proliferator-activated receptor-alpha gene expression signature in SAMP1 mice.

Mol Nutr Food Res. Ubiquinol supplementation activates mitochondria functions to decelerate senescence in senescence-accelerated mice. Antioxid Redox Signal. Improved health-related quality of life, and more days out of hospital with supplementation with selenium and coenzyme Q10 combined. Results from a double-blind, placebo-controlled prospective study. J Nutr Health Aging. Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly.

PLoS One. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice.

Dietary cosupplementation with vitamin E and coenzyme Q 10 inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. Biochem Biophys Res Commun. Neuromuscul Disord. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase ETFDH gene. Coenzyme Q 10 -responsive ataxia: 2-year-treatment follow-up. Mov Disord. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials.

Mayo Clin Proc. Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev. Congestive heart failure. Rakel: Conn's Current Therapy New York: W. Saunders Company; Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA controlled rosuvastatin multinational study in heart failure.

J Am Coll Cardiol. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev. Lei L, Liu Y. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. BMC Cardiovasc Disord. Cardiovasc Res. Coenzyme Q10 regulates antioxidative stress and autophagy in acute myocardial ischemia-reperfusion injury. Oxid Med Cell Longev. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium.

Overview of the use of CoQ10 in cardiovascular disease. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations.

Ann Thorac Surg. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ. Celik T, Iyisoy A. Coenzyme Q10 and coronary artery bypass surgery: what we have learned from clinical trials. High plasma coenzyme Q10 concentration is correlated with good left ventricular performance after primary angioplasty in patients with acute myocardial infarction.

Medicine Baltimore. The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention.

Cardiovasc Ther. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension.

The effects of coenzyme Q10 supplementation on blood pressures among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials.

Effects of coenzyme Q10 supplementation on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials.

Effects of coenzyme Q10 on markers of inflammation: a systematic review and meta-analysis. Supplementation with coenzyme Q10 reduces plasma lipoprotein a concentrations but not other lipid indices: A systematic review and meta-analysis. Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis.

J Clin Pharm Ther. Effect of long-term treatment with antioxidants vitamin C, vitamin E, coenzyme Q10 and selenium on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutr Metab Lond.

Clin Chim Acta. Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q Diabet Med. Maternal transmission of diabetes. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA A to G mutation. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. Altered redox state of platelet coenzyme Q10 in Parkinson's disease.

J Neural Transm. Ann Neurol. Neurosci Lett. The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism Relat Disord. Coenzyme Q10 for patients with Parkinson's disease: a systematic review and meta-analysis. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials.

Neurol Sci. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

J Neurochem. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Burk K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias. Pharmacological therapeutics in Friedreich ataxia: the present state.

Expert Rev Neurother. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Specifically, they substantiate the idea that manipulations of a defective UQ biosynthetic pathway with hydroxylated analogues of 4-HB could benefit patients with some types of primary UQ deficiency.

Although no patients with defects in COQ7 have yet been identified, several independent pathological mutations in COQ6 have been described in UQ-deficient patients Furthermore, a patient with a COQ9 mutation who died at 2 years of age despite UQ 10 therapy has been described It is very likely that patients would very well tolerate the hydroxylated analogues of 4-HB, even at high concentrations. Indeed, both of them, especially 2,4-DHB, have been used as food flavour modifiers because of their sweet taste and ability to enhance the sweetness delivery of other artificial sweeteners.

In fact, 2,4-DHB is present in a broad range of food products and drinks, such as beverages, fish products, snack foods and chewing gums. An important first step to explore the potential use of 4-HB analogues in treatment of human disease would be to test the effects of such treatments on mouse mutants that carry mutations that are analogous to those found in human patients. Considering that there is still some residual biosynthesis of UQ in human patients 17 , 18 and our observation of inhibition of the native UQ biosynthetic pathway in the presence of 2,4-DHB, the possible aggregated effects of bypass and inhibition need to be addressed carefully.

Numerous inborn single gene diseases or disease predispositions are the result of enzymatic deficiency in biosynthetic pathways The disease phenotypes can result from the absence of an essential metabolite or the production and accumulation of toxic intermediates.

Some disease can be alleviated by providing the missing product such as defects in bile acid synthesis 67 or in tyrosine hydroxylase In others, such as classic phenylketonuria, relief is obtained by minimizing the activity of the pathway by starving it of substrate, in this case phenylalanine Our findings suggest that there would be value in exploring more systematically a third approach that consists in providing an alternative bypass precursor that incorporates chemical groups that are normally provided to the end product by the deficient enzymatic step.

This approach might have additional benefits when the intermediates that accumulate are toxic, as a bypass precursor might successfully compete with the natural precursor to lower the levels of toxic intermediate, similar to what we have observed for DMQ Fig.

Females of the same genotype injected with vehicle alone corn oil were used as controls. Unless otherwise stated, experiments were performed on female mice 6 months after the last TM or vehicle administration. For treatment experiments, 2,4-DHB Sigma, 0. Genotyping primers are provided in Supplementary Table 4. Quinones were extracted with a mixture of ethanol and hexane as previous described 9. UQ 6 was used as an internal standard to correct for extraction efficiency.

Total quinone levels were normalized to protein content. Mitochondrial isolation was performed using standard homogenization and differential centrifugation methods similar to previous studies 9 , After washing once, the final pellet was re-suspended in a small volume of the same isolation buffers.

The respiration media contained 0. State 3 respiration was recorded after adding ADP to a final concentration of 0. State 4 respiration was determined as the rate of oxygen consumption after exhaustion of ADP. Data are expressed as nmoles oxygen consumed per min per mg protein.

The extinction coefficient The extinction coefficient for NADH used was 6. Decylubiquinol was prepared by reducing decylubiquinone with sodium dithionite. Specific ETC enzyme activities are calculated by subtraction of values obtained in the presence of specific complex inhibitors and are finally expressed as nmoles of electron acceptor reduced per min per mg mitochondrial protein. The Bradford assay was used to quantify the protein concentration. Activities were calculated as nmol of citrate formed per min per mg of protein using an extinction coefficient of Heart mitochondria 0.

Arbitrary fluorescence was converted to known amounts of H 2 O 2 using standard curves prepared on the same day. Results are expressed as nmoles of H 2 O 2 per min per mg of mitochondrial protein. Physical activity was measured using a comprehensive laboratory animal monitoring system Columbus Instruments.

Mice were housed individually with free access to food and water. Tail blood lactate concentrations were determined using a lactate meter Lactate Plus in resting mice.

Blood glucose was measured every week for 3—4 weeks and a mean value was obtained for each individual mouse. Lactate measurement was done twice with an interval of 1 week. The Infinity Triglyceride reagent kit Thermo Scientific was used to determine plasma triglyceride levels. The protein loading was monitored with an anti-porin antibody ,, mouse monoclonal; Abcam.

After three washing steps with PBS 0. Band densities were quantified using Thermo Scientific myImageAnalysis software. The sample sizes used were based on the variability expected and previous experience. In experiments involving animals, there were no exclusions. No randomization methods were used. Differences between survival curves were evaluated with the log-rank test. All time-course data were analysed using a two-way analysis of variance ANOVA coupled with a Bonferroni post hoc test.

How to cite this article: Wang, Y. Mitochondrial function and lifespan of mice with controlled ubiquinone biosynthesis. Turunen, M. Metabolism and function of coenzyme Q. Acta , — Lenaz, G. Mobility and function of coenzyme Q ubiquinone in the mitochondrial respiratory chain.

Chen, Q. Production of reactive oxygen species by mitochondria: central role of complex III. Treberg, J. Evidence for two sites of superoxide production by mitochondrial NADH-ubiquinone oxidoreductase complex I. Bentinger, M. The antioxidant role of coenzyme Q. Mitochondrion 7 Suppl , S41—S50 Article Google Scholar. Wang, Y. Molecular genetics of ubiquinone biosynthesis in animals.

Jonassen, T. A dietary source of coenzyme Q is essential for growth of long-lived Caenorhabditis elegans clk-1 mutants. Natl Acad. USA 98 , — Jiang, N. Mouse CLK-1 is imported into mitochondria by an unusual process that requires a leader sequence but no membrane potential.

Mitochondrial respiration without ubiquinone biosynthesis. Xie, L. Overexpression of the Coq8 kinase in Saccharomyces cerevisiae coq null mutants allows for accumulation of diagnostic intermediates of the coenzyme Q6 biosynthetic pathway. Salviati, L. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. Quinzii, C. A mutation in para-hydroxybenzoate-polyprenyl transferase COQ2 causes primary coenzyme Q10 deficiency. Mollet, J. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures.

Lopez, L. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 PDSS2 mutations. Lagier-Tourenne, C. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Heeringa, S. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. Duncan, A. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease.

Diomedi-Camassei, F. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. Hirano, M. Rotig, A. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet , — Nakai, D. Lapointe, J. Cell Biol. Lu, S. Cerebellar defects in Pdss2 conditional knockout mice during embryonic development and in adulthood.

Hughes, B. A mild impairment of mitochondrial electron transport has sex-specific effects on lifespan and aging in mice. Sohal, R. Oxidative stress, caloric restriction, and aging. Science , 59—63 Park, C.

Mitochondrial DNA mutations in disease and aging. Wallace, D. The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev.

Seo, A. New insights into the role of mitochondria in aging: mitochondrial dynamics and more. Cell Sci. Dillon, L. The role of PGC-1 coactivators in aging skeletal muscle and heart.

Short, K. Decline in skeletal muscle mitochondrial function with aging in humans. USA , — Ojaimi, J. Mitochondrial respiratory chain activity in the human brain as a function of age. Ageing Dev. Filosto, M. The role of mitochondria in neurodegenerative diseases.

Lopez-Otin, C. The hallmarks of aging. Cell , — Gomes, A. Yee, C. The intrinsic apoptosis pathway mediates the pro-longevity response to mitochondrial ROS in C. Hekimi, S. Trends Cell Biol. Hayashi, S.

Thelin, A. Half-life of ubiquinone-9 in rat tissues. FEBS Lett. Peng, M. Primary coenzyme Q deficiency in Pdss2 mutant mice causes isolated renal disease. PLoS Genet. Trifunovic, A. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature , — Chen, H. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. Larsson, N.

Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice.